EDIT - Editas Medicine, Inc.
| Previous Close | 30.41 |
| Open | 30.69 |
| Bid | 31.59 x 900 |
| Ask | 31.64 x 1000 |
| Day's Range | 30.45 - 31.86 |
| 52 Week Range | 17.88 - 45.02 |
| Volume | 310,700 |
| Avg. Volume | 960,571 |
| Market Cap | 1.509B |
| Beta | 3.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.99 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.20 |
- Thomson Reuters StreetEvents•4 hours ago
Edited Transcript of EDIT earnings conference call or presentation 6-Aug-18 9:00pm GMT
Q2 2018 Editas Medicine Inc Earnings Call
- Motley Fool•7 hours ago
The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed
Get ready for a golden age of medicine that could dramatically shake up which biotechs get the gold.
- Motley Fool•2 days ago
3 Hot Trends Warren Buffett Is Missing Out On -- But You Don't Have To
The Oracle of Omaha hasn't invested in these areas. But they're great opportunities for investors who aren't already billionaires.
- GlobeNewswire•5 days ago
Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
Editas Medicine, Inc. (EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) completed the NIH protocol registration process for EDIT-101. The NIH determined a public meeting is not necessary, and the RAC will not be convened to review this clinical trial. EDIT-101 is Editas Medicine’s experimental CRISPR genome editing medicine for the treatment of Leber Congenital Amaurosis type 10 (LCA10).
- Zacks•8 days ago
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
- Zacks•11 days ago
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
- Zacks•11 days ago
Options Traders Expect Huge Moves in Editas Medicine (EDIT) Stock
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Market Realist•11 days agoMajor Collaborations Bode Well for Editas Medicine
In May 2018, Editas Medicine (EDIT) and Juno Therapeutics amended and restated their 2015 collaboration and license agreement. This collaboration is focused on researching and developing engineered T cells with chimeric antigen receptors (or CARs) and T cell receptors (or TCRs) that are genetically modified to kill other cells. Editas Medicine entered a strategic alliance and option agreement with Allergan Pharmaceuticals in March 2017 for discovering, developing, and commercializing new gene editing products targeted at ocular diseases.
Market Realist•11 days agoHow Editas Medicine Performed in the Second Quarter
Editas Medicine (EDIT) generated collaboration and research and development revenues of $7.37 million in the second quarter of 2018 compared with $3.1 million in the second quarter of 2017. This increase was attributable to the $3.9 million the company received under a license agreement with Beam Therapeutics and $2.8 million higher revenues recognized under a collaboration agreement with Juno Therapeutics.
Market Realist•11 days agoHow Analysts Rate Editas Medicine and Peers in August
Editas Medicine (EDIT) is a research-stage genome editing company. Editas makes use of clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology and has developed a proprietary genome editing platform based on it with a product development strategy to chiefly target genetically defined diseases.
- Motley Fool•12 days ago
Editas Prepares for the Commercialization of EDIT-101
The genome-editing specialist just offered its latest update on the state of the business. Here's what investors need to know.
Motley Fool•13 days agoEditas Medicine (EDIT) Q2 2018 Earnings Conference Call Transcript
EDIT earnings call for the period ending June 30, 2018.
- ACCESSWIRE•14 days ago
Today's Research Reports on Trending Tickers: Editas Medicine and Ligand Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related ...
- Zacks•15 days ago
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -18.84% and 18.90%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•15 days ago
Editas: 2Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 82 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
- GlobeNewswire•15 days ago
Editas Medicine Announces Second Quarter 2018 Results and Update
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States. Plan to file EDIT-101 Investigational ...
- PR Newswire•15 days ago
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
DUBLIN and CAMBRIDGE, Mass., Aug. 6, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.
- GlobeNewswire•15 days ago
Allergan and Editas Medicine Announce Exercise of Options to Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101
Allergan plc (AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that Allergan’s wholly-owned subsidiary, Allergan Pharmaceuticals International Limited (Allergan), has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States.
- ACCESSWIRE•15 days ago
Editas Medicine, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Editas Medicine, Inc. (NASDAQ: EDIT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 5:00 PM Eastern Time. ...
- Motley Fool•19 days ago
David Looks Ahead: 1 Massive Trend, 10 Hot Stocks, and 1 Vital Piece of Advice
Gardner foresees one particular technology becoming as ubiquitous as Wi-Fi.
- Motley Fool•19 days ago
FoolFest 2018: The Gardner Brothers Look Back -- and Ahead
Not every Fool fan can make it to Alexandria, Virginia, for our big member shindig, so we’re bringing you one of the highlights.
Market Realist•21 days agoWhat to Expect from Editas Medicine’s Q2 2018 Earnings
Editas Medicine (EDIT) is expected to report its second-quarter earnings results on August 8. In this series, we’ll take a look at analysts’ expectations for the company’s top line, operational performance, and bottom line performance in the quarter along with their recommendations for its stock. Editas Medicine is a clinical-stage genome editing company.
Market Realist•21 days agoWhy Editas Medicine Stock Fell in July
Editas Medicine’s (EDIT) general and administrative expenses are expected to rise 39.57% YoY (year-over-year) from $11.89 million to $16.60 million in the second quarter, and its research and development expenses are expected to increase 39.16% YoY from $17.32 million to $24.10 million in the second quarter. Editas Medicine is expected to have a net income of -$32.88 million in the second quarter compared to its net income of -$26.44 million in the second quarter of 2017. This net income translates to a net income per share of -$0.67 in the second quarter of 2018 compared to a net income per share of -$0.65 in the second quarter of 2017.
Market Realist•21 days agoWhy These Gene-Editing Companies Took a Tumble in July
The stock prices of gene-editing companies like CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA) saw a sharp correction in July. These companies are focused on clustered, regularly interspaced, short palindromic repeats (or CRISPR) technology, and have fallen on concerns stemming from a recently published study.
- GlobeNewswire•22 days ago
Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results
CAMBRIDGE, Mass., July 30, 2018-- Editas Medicine, Inc., a leading genome editing company, today announced that it will host a conference call and webcast on Monday, August 6, 2018, at 5:00 p.m. ET to ...
